{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"217","upperLimit":"218","value":"217"},{"groupId":"OG001","lowerLimit":"191","upperLimit":"284","value":"218"},{"groupId":"OG002","lowerLimit":"278","upperLimit":"278","value":"278"},{"groupId":"OG003","lowerLimit":"174","upperLimit":"219","value":"196"},{"groupId":"OG004","lowerLimit":"135","upperLimit":"160","value":"139"},{"groupId":"OG005","lowerLimit":"189","upperLimit":"189","value":"189"},{"groupId":"OG006","lowerLimit":"192","upperLimit":"198","value":"195"},{"groupId":"OG007","lowerLimit":"158","upperLimit":"217","value":"199"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"title":"AMG 224 Conjugated Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"194","upperLimit":"215","value":"201"},{"groupId":"OG001","lowerLimit":"193","upperLimit":"249","value":"221"},{"groupId":"OG003","lowerLimit":"159","upperLimit":"220","value":"189"},{"groupId":"OG004","lowerLimit":"155","upperLimit":"300","value":"243"},{"groupId":"OG005","lowerLimit":"164","upperLimit":"164","value":"164"},{"groupId":"OG006","lowerLimit":"179","upperLimit":"179","value":"179"},{"groupId":"OG007","lowerLimit":"174","upperLimit":"280","value":"241"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"title":"AMG 224 Conjugated Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"231","upperLimit":"238","value":"234"},{"groupId":"OG001","lowerLimit":"198","upperLimit":"198","value":"198"},{"groupId":"OG003","lowerLimit":"197","upperLimit":"287","value":"242"},{"groupId":"OG004","lowerLimit":"51.0","upperLimit":"189","value":"155"},{"groupId":"OG005","lowerLimit":"238","upperLimit":"238","value":"238"},{"groupId":"OG006","lowerLimit":"170","upperLimit":"170","value":"170"},{"groupId":"OG007","lowerLimit":"172","upperLimit":"216","value":"194"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"}],"units":"Participants"}],"title":"Total Anti-BCMA Antibody after Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"250","upperLimit":"277","value":"269"},{"groupId":"OG001","lowerLimit":"255","upperLimit":"255","value":"255"},{"groupId":"OG003","lowerLimit":"211","upperLimit":"249","value":"230"},{"groupId":"OG004","lowerLimit":"351","upperLimit":"351","value":"351"},{"groupId":"OG006","lowerLimit":"147","upperLimit":"147","value":"147"},{"groupId":"OG007","lowerLimit":"157","upperLimit":"290","value":"199"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"title":"Total Anti-BCMA Antibody after Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"50.2","upperLimit":"50.2","value":"50.2"},{"groupId":"OG005","lowerLimit":"52.1","upperLimit":"52.1","value":"52.1"},{"groupId":"OG007","lowerLimit":"48.8","upperLimit":"48.8","value":"48.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"DM1 after Cycle 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"DM1 after Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"description":"The t1/2,z of AMG 224 conjugated antibody, total anti-BCMA antibody and total unconjugated DM1 was measured.","dispersionType":"Full Range","groups":[{"description":"Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG000","title":"Dose Exploration: AMG 224 Dose A"},{"description":"Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG001","title":"Dose Exploration: AMG 224 Dose B"},{"description":"Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG002","title":"Dose Exploration: AMG 224 Dose C"},{"description":"Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG003","title":"Dose Exploration: AMG 224 Dose D"},{"description":"Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG004","title":"Dose Exploration: AMG 224 Dose E"},{"description":"Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG005","title":"Dose Exploration: AMG 224 Dose F"},{"description":"Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG006","title":"Dose Exploration: AMG 224 Dose G"},{"description":"All participants in Dose Expansion who had prior treatment or no prior treatment with a CD38-targeting antibody were administered the MTD of AMG 224 identified in the dose escalation as 3 mg/kg. AMG 224 was administered as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.","id":"OG007","title":"Dose Expansion: AMG 224 3 mg/kg"}],"paramType":"MEDIAN","populationDescription":"The PK parameter analysis set included participants who received at least 1 dose of AMG 224 and for whom PK parameters could be adequately estimated. All participants included in the overall number of participants analyzed contributed data to this endpoint.","reportingStatus":"POSTED","timeFrame":"AMG 224 and anti-BCMA antibody: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, 96 hours, 168 hours, and 336 hours post-dose (Cycles 1 + 2); DM1: pre-dose, 0.5 hours, EOI, 4 hours, 24 hours, and 96 hours post-dose (Cycles 1 + 2)","title":"Terminal Half-life (t1/2,z) of AMG 224 Conjugated Antibody, Total Anti-BCMA Antibody, and Total Unconjugated DM1","type":"SECONDARY","unitOfMeasure":"hours"}